American Portfolios Advisors’s Sarepta Therapeutics SRPT Stock Holding History

American Portfolios Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$12.8K	Hold	116	–	–	﹤0.01%	2407
2022 Q2	$8.7K	Hold	116	–	–	﹤0.01%	2625
2022 Q1	$9.06K	Hold	116	–	–	﹤0.01%	2730
2021 Q4	$10.4K	Hold	116	–	–	﹤0.01%	2604
2021 Q3	$10.7K	Sell	116 -170	-59%	-$13.1K	﹤0.01%	2538
2021 Q2	$22.2K	Sell	286 -83	-22%	-$6.29K	﹤0.01%	2174
2021 Q1	$27.5K	Buy	369 +9	+3%	+$830	﹤0.01%	1890
2020 Q4	$61.4K	Buy	360 +2	+0.6%	+$296	﹤0.01%	1348
2020 Q3	$50.3K	Buy	358 +162	+83%	+$24.6K	﹤0.01%	1318
2020 Q2	$31.4K	Hold	196	–	–	﹤0.01%	1460
2020 Q1	$19.2K	Sell	196 -10	-5%	-$1.14K	﹤0.01%	1543
2019 Q4	$26.6K	Buy	+206	New	+$20.8K	﹤0.01%	1613
2018 Q2	–	Sell	-350	Closed	-$25.9K	–	2431
2018 Q1	$25.9K	Buy	350 +50	+17%	+$3.33K	﹤0.01%	1294
2017 Q4	$16.7K	Buy	+300	New	+$15.9K	﹤0.01%	1389

Other funds holding SRPT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

American Portfolios Advisors's SRPT Position: Q3 2022 in Review

American Portfolios Advisors held its Sarepta Therapeutics (SRPT) position steady in Q3 2022 at 116 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2407.

American Portfolios Advisors first reported a position in SRPT in Q4 2017 and has held it in 14 quarters since. The position peaked at $61.4K in Q4 2020. 375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

American Portfolios Advisors held 116 shares of Sarepta Therapeutics worth $12.8K as of Q3 2022.
American Portfolios Advisors left its Sarepta Therapeutics share count unchanged in Q3 2022.
Sarepta Therapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #2407 holding.
American Portfolios Advisors first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 14 quarters since.
American Portfolios Advisors's Sarepta Therapeutics position peaked at $61.4K in Q4 2020.
375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.